Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer

References

• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161–74
   PubMed Web of Science ®Google Scholar
• Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998; 161: 6845–52
   PubMed Web of Science ®Google Scholar
• Yoshiji H, Harris SR, Raso E, Gomez DE, Lindsay CK, Shibuya M, et al. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 1998; 75: 81–7
   PubMed Web of Science ®Google Scholar
• Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992; 298: 29–32
   PubMed Web of Science ®Google Scholar
• Chesler L, Golde DW, Bersch N, Johnson MD. Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood 1995; 86: 4506–15
   PubMed Web of Science ®Google Scholar
• Wang T, Yamashita K, Iwata K, Hayakawa T. Both tissue inhibitors of metalloproteinases-1 (TIMP-1) and TIMP-2 activate ras but through different pathways. Biochem Biophys Res Comm 2002; 296: 201–5
   PubMedGoogle Scholar
• Porter JF, Shen S, Denhardt DT. Tissue inhibitor of metalloproteinase-1 stimulates proliferation of human cancer cells by inhibiting a metalloproteinase. Br J Cancer 2004; 90: 463–70
   PubMed Web of Science ®Google Scholar
• Boudreau N, Sympson CJ, Werb Z, Bissell MJ. Suppression of ice and apoptosis in mammary epithelial cells by extracellular-matrix. Science 1995; 267: 891–3
   PubMed Web of Science ®Google Scholar
• Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A, et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 1998; 102: 2002–10
   PubMed Web of Science ®Google Scholar
• Lambert E, Boudot C, Kadri Z, Soula-Rothhut M, Sowa ML, Mayeux P, et al. Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival. Biochem J 2003; 372: 767–74
   PubMed Web of Science ®Google Scholar
• Liu XW, Bernardo MM, Fridman R, Kim HRC. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and the MAPK signalling pathway. J Biol Chem 2003; 278: 40364–72
   PubMed Web of Science ®Google Scholar
• Lu XQ, Levy M, Weinstein IB, Santella RM. Immunological quantitation of levels of tissue inhibitor of metalloproteinase-1 in human colon cancer. Cancer Res 1991; 51: 6231–5
   PubMedGoogle Scholar
• Zeng ZS, Guillem JG. Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 MRNA expression in human colorectal cancer and liver metastases. Br J Cancer 1995; 72: 575–82
   PubMed Web of Science ®Google Scholar
• Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, Haraguchi M, et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer 1997; 76: 531–6
   PubMed Web of Science ®Google Scholar
• Joo YE, Seo KS, Kim HS, Rew JS, Park CS, Kim SJ. Expression of Tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer. Dig Dis Sci 2000; 45: 114–21
   PubMed Web of Science ®Google Scholar
• McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N, Duffy MJ. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999; 84: 44–8
   PubMed Web of Science ®Google Scholar
• Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 1997; 3: 1623–8
   PubMed Web of Science ®Google Scholar
• Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004; 10: 2289–98
   PubMed Web of Science ®Google Scholar
• Wurtz SO, Christensen IJ, Schrohl AS, Mouridsen H, Lademann U, Jensen V, et al. Measurement of the uncomplexed fraction of tissue inhibitor of metalloproteinases-1 in the prognostic evaluation of primary breast cancer patients. Mol Cell Proteomics 2005; 4: 483–91
   PubMed Web of Science ®Google Scholar
• Cooper TW, Eisen AZ, Stricklin GP, Welgus HG. Platelet-derived collagenase inhibitor: characterization and subcellular localization. Proc Natl Acad Sci 1985; 82: 2779–83
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer-Hansen G, et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999; 80: 495–503
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, et al. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 2002; 8: 156–64
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Christensen IJ, Nielsen HJ, Lilja H, Murphy G, Jensen V, et al. Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases i in plasma by immunoassay. Clin Chem 2002; 48: 1305–13
   PubMed Web of Science ®Google Scholar
• Kodama S, Yamashita K, Kishi J, Iwata K, Hayakawa T. A sandwich enzyme-immunoassay for collagenase inhibitor using monoclonal-antibodies. Matrix 1989; 9: 1–6
   PubMedGoogle Scholar
• Simpson RA, Hemingway DM, Thompson MM. Plasma TIMP-1: a marker of metastasis in colorectal cancer. Colorectal Dis 2000; 2: 100–5
   PubMedGoogle Scholar
• Zucker S, Lysik RM, Dimassimo BI, Zarrabi HM, Moll UM, Grimson R, et al. Plasma assay of gelatinase-B: tissue inhibitor of metalloproteinase complexes in cancer. Cancer 1995; 76: 700–8
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W, et al. High preoperative plasma tissue inhibitors of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 2000; 6: 4292–9
   PubMed Web of Science ®Google Scholar
• Yukawa N, Yoshikawa T, Akaike M, Sugimusa Y, Takemiya S, Yanoma S, et al. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma. Br J Surg 2001; 88: 1596–601
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Christensen IJ, Nilbert M, Bendahl PO, Nielsen HJ, Brunner N, et al. Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival: a validation study. Eur J Cancer 2004; 40: 64–72
   PubMed Web of Science ®Google Scholar
• Yukawa N, Yoshikawa T, Akaike M, Sugimasa Y, Takemiya S, Yanoma S, et al. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer. Anticancer Res 2004; 24: 2101–5
   PubMed Web of Science ®Google Scholar
• Waas ET, Hendriks T, Lomme RM, Wobbes T. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 2005; 48: 700–10
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Nielsen HJ, Sorensen S, Jensen V, Brunner N, Christensen IJ. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer. Eur J Cancer 2006; 42: 1889–96
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Hansen U, Brunner N, Nielsen HJ, Illemann M, Nielsen BS. Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int J Cancer 2005; 113: 198–206
   PubMed Web of Science ®Google Scholar
• Cooksley S, Hipkiss JB, Tickle SP, Holmesievers E, Docherty AJP, Murphy G, et al. Immunoassays for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes. Matrix 1990; 10: 285–91
   PubMedGoogle Scholar
• Holten-Andersen MN, Brunner N, Maimonis P, Jensen V, Murphy G, Piironen T. Characterization of monoclonal antibodies to tissue inhibitor of metalloproteinases-1. J Clin Ligand Assay 2002; 25: 87–90
   Google Scholar
• Sørensen NM, Dowell BL, Stewart KD, Jensen V, Larsen L, Lademann U, et al. Establishment and characterization of 7 new monoclonal antibodies to tissue inhibitor of metalloproteinases-1. Tumour Biol 2005; 26: 71–80
   PubMedGoogle Scholar
• Holten-Andersen MN, Schrohl AS, Brunner N, Nielsen HJ, Hogdall CK, Hogdall EV. Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay. Int J Biol Markers 2003; 18: 170–6
   PubMed Web of Science ®Google Scholar
• Schrohl AS, Christensen IJ, Pedersen AN, Jensen V, Mouridsen H, Murphy G, et al. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics 2003; 2: 164–72
   PubMed Web of Science ®Google Scholar
• Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999; 189: 487–95
   PubMed Web of Science ®Google Scholar
• Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. cancer metastasis Rev 2006; 25: 99–113
   PubMed Web of Science ®Google Scholar